Sarep­ta's con­fir­ma­to­ry Duchenne tri­al fails to meet end­point, com­pli­cat­ing fu­ture for con­tro­ver­sial drug

Sarep­ta and Roche’s con­fir­ma­to­ry study for a Duchenne gene ther­a­py failed to hit its pri­ma­ry end­point, com­pli­cat­ing plans to con­vert the drug’s la­bel in­to a full ap­proval for a wider pop­u­la­tion of boys.

In the Phase III EM­BARK study, 125 pa­tients re­ceived ei­ther place­bo or Ele­v­idys, the gene ther­a­py de­vel­oped by Sarep­ta. Af­ter one year, those who re­ceived Ele­v­idys saw a 2.6-point im­prove­ment com­pared to a 1.9-point im­prove­ment in the place­bo group on a func­tion­al mo­bil­i­ty scale called the North Star Am­bu­la­to­ry As­sess­ment, the com­pa­nies said Mon­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER